Pricing Log in Create free account
Saturday 7 November 2026 Export ENTA’s income statement to Excel — free account

Enanta Pharmaceuticals, Inc.

ENTA Healthcare Biotechnology

Enanta Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $65.3 million, down 3.42% from fiscal 2024.

Revenue
−21.6%
EPS
+21.2%
Free cash flow
−157.5%

Quarter to June 2026, against a year earlier

11.00 0.92 +9.13%
Market cap
$293.6M
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
4/9
Altman Z
−1.41
Beneish M
−4.29
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.18
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 9 — — — — — — — — — — —
Insider Ownership 4.61%

Capital & Financial Ratios $m

Size
Market Cap 293.59
Revenue ttm 65.26
Net income ttm (63.23)
Free cash flow ttm (36.94)
Net debt Q (189.51)
Valuation
P/E 0.00
Forward P/E (4.80) (negative: loss-making)
Price / sales 4.90
Forward P/S Powerpack
Price / FCF 0.00
Price / book 3.17
Financial health
Current ratio Q 3.76 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (4.17)
Growth
Revenue growth Q −21.60% (below 0%: shrinking)
Operating income growth Q +8.77% (above 0%: growing)
EPS, this year +40.29% (at or above 15%: strong)
EPS, next year A +4.13%
Revenue, next year A −2.03% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +11.43%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.0×, against a ten-year median of 4.3×; over the ten years it ranged from −2.3× in 2023 to 17.6× in 2017.
P/S against its own 10 years 26.47%
10-year low 10-year high
P/B against its own 10 years 68.00%
10-year low 10-year high
EV/Sales against its own 10 years 7.87%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 370 249 189 190
Receivables 40 39 7 7
Inventory — — — —
Other — — — —
423 300 204 204
2023 2024 2025 Q'26
Payables 4 8 2 3
ST’ Debt — — — —
Other 35 34 31 37
63 58 49 54

Compound Annual Growth %

10y 5y 3y
Sales (8.62%) (11.81%) (8.82%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (12.14%) (32.32%) (41.38%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.37 Actual −0.67

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −1.13 −0.87 Beat by 0.26
Q1 FY26 −0.54 −0.42 Beat by 0.12
Q2 FY26 −0.46 −0.45 Beat by 0.01
Q3 FY26 −0.37 −0.67 Miss by 0.30
Q4 FY26 −0.83 — Reports 16 November 2026

EPS $

Dec Mar Jun Sep Year
’26 (0.42) (0.45) (0.67) — —
’25 (1.05) (1.06) (0.85) (0.87) (3.84)
’24 (1.58) (1.47) (1.07) (1.36) (5.48)
’23 (1.39) (1.79) (1.86) (1.33) (6.38)
’22 (1.48) (1.63) (1.53) (1.27) (5.91)
’21 (0.41) (1.09) (1.19) (1.22) (3.92)
’20 0.65 (0.30) (0.71) (1.46) (1.81)
Fiscal quarters ending in the months shown.

Revenue $m

Dec Mar Jun Sep Year
’26 19 17 14 — —
’25 17 15 18 15 65
’24 18 17 18 15 68
’23 24 18 19 19 79
’22 28 19 19 20 86
’21 32 20 22 24 97
’20 53 28 19 24 122
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Dec Mar Jun Sep Year
’26 (12) (7) (10) — —
’25 (17) (13) 18 (6) (19)
’24 (25) (29) (15) (10) (79)
’23 (36) (14) (32) (22) (103)
’22 (13) (26) (30) (16) (85)
’21 (15) (5) (30) (21) (70)
’20 12 15 (4) (15) 7
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Dec Mar Jun Sep Year
’26 (12) (7) (10) — —
’25 (26) (16) 17 (8) (32)
’24 (26) (30) (21) (19) (97)
’23 (39) (16) (34) (23) (112)
’22 (14) (26) (30) (17) (87)
’21 72 (92) (30) (21) (71)
’20 93 (66) (5) (16) 6
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to September

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 88 103 207 205 122 97 86 79 68 65 65 (3.3%) 64 64 86 +9.8%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.0 pt
EBT 33 27 93 46 (35) (108) (122) (131) (118) (84) (63) n/m
EBT margin, % 36.89 26.21 45.07 22.20 (28.59) (110.82) (141.82) (165.39) (174.15) (127.90) (96.74) (164.8) pt
Net income 22 18 72 46 (36) (79) (122) (134) (116) (82) (63) n/m
Per share, $
Per share, $ Revenue 4.66 5.39 10.73 10.48 6.14 4.81 4.18 3.78 3.20 3.06 2.24 (4.6%)
Earnings 1.14 0.93 3.74 2.37 (1.81) (3.92) (5.91) (6.38) (5.48) (3.84) (2.41) n/m
Cash flow 1.89 2.76 1.52 3.65 0.36 (3.47) (4.11) (4.92) (3.72) (0.90) (1.21) n/m
Capex (0.25) (0.13) (0.15) (0.28) (0.07) (0.04) (0.10) (0.43) (0.85) (0.60) (0.06) +10.3%
Free cash flow 1.64 2.63 1.36 3.37 0.28 (3.51) (4.22) (5.35) (4.57) (1.51) (1.27) n/m
Book value 14.26 15.82 20.45 23.62 22.85 19.80 15.60 10.34 6.09 3.03 3.47 (15.8%)
Shares, m 19 19 19 20 20 20 21 21 21 21 27 +1.3%
Valuation, ×
Valuation, × P/E 23.14 51.15 22.61 25.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.2
P/S 5.71 8.82 7.84 5.73 7.45 11.80 12.40 2.78 3.24 3.91 4.90 7.0
P/B 1.87 3.01 4.11 2.54 2.00 2.87 3.33 1.01 1.70 3.95 3.17 2.6
EV/Sales 3.33 6.65 6.34 4.10 4.30 9.29 9.51 (1.89) (0.44) 1.02 2.00 4.2
EV/FCF 9.45 13.63 49.96 12.75 93.25 (12.75) (9.43) 1.34 0.31 (2.07) (3.53) 15.6
Cash, $m
Cash, $m Operating cash flow 36 53 29 71 7 (70) (85) (103) (79) (19) (35) n/m
Capex (5) (3) (3) (5) (1) (1) (2) (9) (18) (13) (2) +11.8%
Free cash flow 31 50 26 66 6 (71) (87) (112) (97) (32) (37) n/m
Balance, $m
Balance, $m Working capital 224 217 364 379 413 283 282 360 242 156 149 (4.0%)
Net debt (210) (224) (309) (335) (387) (244) (249) (370) (249) (189) (190) (1.2%)
Shareholders’ equity 270 302 394 462 456 399 321 217 129 65 101 (14.7%)
Returns, %
Returns, % ROA 8.22 5.83 19.42 10.26 (7.41) (17.08) (29.91) (31.95) (27.67) (24.91) (21.15) (33.1) pt
ROIC 32.21 19.72 64.99 18.04 (37.75) (44.06) (107.35) 0.00 0.00 0.00 0.00 (32.2) pt
ROE 8.56 6.20 20.70 10.83 (7.88) (18.48) (33.79) (49.74) (67.17) (84.63) (70.12) (93.2) pt
People
People Employees 76 89 113 132 141 155 160 145 131 120 — +5.2%
Revenue/emp, $m 1.16 1.16 1.83 1.55 0.87 0.63 0.54 0.55 0.52 0.54 — (8.1%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026

Enanta Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
XFOR X4 Pharmaceuticals, Inc. $304.4M — (loss-making) — (loss-making) +63.12% (above 0%: growing) n/m +27.45% (above 0%: growing) 82.18% (694.37%) Compare
BNTC Benitec Biopharma Limited $301.5M — (loss-making) — (loss-making) −85.42% (below 0%: shrinking) n/m +38.90% (above 0%: growing) 0.00% 0.00% Compare
GALT Galectin Therapeutics Inc. $301.0M — (loss-making) — — n/m +63.06% (above 0%: growing) 0.00% 0.00% Compare
ENTA Enanta Pharmaceuticals, Inc. $293.6M — (loss-making) — (loss-making) −21.60% (below 0%: shrinking) n/m −157.51% (below 0%: shrinking) 100.00% (120.04%)
SCTX Scribe Therapeutics Inc. $293.1M — — — n/m — 100.00% (489.83%) Compare
AGEN Agenus Inc. $290.8M 10.7× 27.7× +4.14% (above 0%: growing) −99.00% (below 0%: shrinking) −37.06% (below 0%: shrinking) 100.00% 36.23% Compare
KYTX Kyverna Therapeutics, Inc. $285.1M — (loss-making) — (loss-making) — n/m −27.06% (below 0%: shrinking) — 0.00% Compare
PRLD Prelude Therapeutics Incorporated $283.7M — (loss-making) — (loss-making) +42.60% (above 0%: growing) n/m +40.32% (above 0%: growing) 100.00% (270.93%) Compare
FULC Fulcrum Therapeutics, Inc. $280.8M — (loss-making) — (loss-making) +27,018.64% (above 0%: growing) n/m −13.05% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $292.0M — — +42.60% — +27.45% 100.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 26 January 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 2.77m 3.60m 23.00
2024 2.70m 2.19m 20.00
2023 7.86m (2.47m) 22.00

Ownership

Directors and executive officers, together 11.48%
Janus Henderson Group plc and certain affiliates 12.04%
Farallon Capital Management, LLC 7.31%
Krensavage Asset Management, LLC 7.29%
Vanguard Group, Inc. 6.68%
BlackRock Inc. 6.32%
Jay R. Luly, Ph.D. 5.85%
Deep Track Capital, LP and certain affiliates 5.12%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Enanta Pharmaceuticals, Inc. (ENTA) Latest News

28 Oct

Impact 3 · · Business Wire

26 Oct

Impact 4 · · Business Wire

13 Oct

Impact 3 · · Business Wire

10 Aug

Impact 3 ·

23 Jun

Impact 3 · · Business Wire

18 Jun

Impact 4 ·

11 May

Impact 3 · · Zacks
Impact 3 · · Business Wire

4 May

Impact 3 · · Business Wire

7 Apr

Impact 3 · · Business Wire

30 Mar

Impact 3 · · Business Wire

15 Mar

Impact 4 · · MarketBeat

12 Feb

Impact 4 · · Zacks

10 Feb

Impact 3 · · Business Wire

9 Feb

Impact 3 · · Zacks
Impact 3 ·
Impact 3 · · Business Wire

15 Jan

Impact 4 · · pharmaceutical-technology.com

8 Jan

Impact 4 · · Business WireZacksZacksClinical Trials ArenaZacksZacksMT NewswiresMT Newswires

5 Jan

Impact 3 ·

1 Jan

Impact 3 · · Simply Wall St.

22 Dec

Impact 3 · · Zacks

21 Nov

Impact 4 · · ZacksZacksZacksZacksZacksZacksZacks

17 Nov

Impact 3 · · Business WireMotley FoolGuruFocus.comGuruFocus.comZacksMotley FoolMotley FoolZacks

4 Nov

Impact 4 · · Simply Wall St.

20 Oct

Impact 4 · · Business Wire

7 Oct

Impact 4 · · Business Wire

2 Oct

Impact 3 · · Business Wire

30 Sep

Impact 3 · · Business Wire
Impact 3 · · clinicaltrialsarena.com
stockrow.com/ENTA · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com